-
-
-
-
-
-
-
Immunomedics (IMMU) has appointed Harout Semerjian as President and CEO
-
-
-
-
-
-
-
IMMUNOMEDICS PROVIDES COVID-19 BUSINESS CONTINUITY UPDATE, AFFIRMS 2020 STRATEGIC PRIORITIES, AND SHARES R&D AND REGULATORY UPDATE
-
-
-
-
-
-
-
Immunomedics Announces FDA Acceptance for Filing of Biologics License Application Resubmission for Sacituzumab Govitecan to Treat Metastatic Triple-Negative Breast Cancer
-
-
-
-
-
-
-
Immunomedics (IMMU) Reports FDA Acceptance of Biologics License Application for Filing and Granted Priority Review for Sacituzumab Govitecan
-
-
15,422 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

